Tracking tDCS induced grey matter changes in episodic migraine: a randomized controlled trial.

Simon Schading, Heiko Pohl, Andreas Gantenbein, Roger Luechinger, Peter Sandor, Franz Riederer, Patrick Freund, Lars Michels
Author Information
  1. Simon Schading: Spinal Cord Injury Centre Balgrist, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  2. Heiko Pohl: Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
  3. Andreas Gantenbein: Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
  4. Roger Luechinger: Institute for Biomedical Engineering, ETH Zurich and University of Zurich, Zurich, Switzerland.
  5. Peter Sandor: Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
  6. Franz Riederer: Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
  7. Patrick Freund: Spinal Cord Injury Centre Balgrist, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  8. Lars Michels: Department of Neuroradiology, University Hospital Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland. lars.michels@usz.ch.

Abstract

BACKGROUND: Occipital transcranial direct current stimulation (tDCS) is an effective and safe treatment for migraine attack prevention. Structural brain alterations have been found in migraineurs in regions related to pain modulation and perception, including occipital areas. However, whether these structural alterations can be dynamically modulated through tDCS treatment is understudied.
OBJECTIVE: To track longitudinally grey matter volume changes in occipital areas in episodic migraineurs during and up to five months after occipital tDCS treatment in a single-blind, and sham-controlled study.
METHODS: 24 episodic migraineurs were randomized to either receive verum or sham occipital tDCS treatment for 28 days. To investigate dynamic grey matter volume changes patients underwent structural MRI at baseline (prior to treatment), 1.5 months and 5.5 months (after completion of treatment). 31 healthy controls were scanned with the same MRI protocol. Morphometry measures assessed rate of changes over time and between groups by means of tensor-based morphometry.
RESULTS: Before treatment, migraineurs reported 5.6 monthly migraine days on average. A cross-sectional analysis revealed grey matter volume increases in the left lingual gyrus in migraineurs compared to controls. Four weeks of tDCS application led to a reduction of 1.9 migraine days/month and was paralleled by grey matter volume decreases in the left lingual gyrus in the treatment group; its extent overlapping with that seen at baseline.
CONCLUSION: This study shows that migraineurs have increased grey matter volume in the lingual gyrus, which can be modified by tDCS. Tracking structural plasticity in migraineurs provides a potential neuroimaging biomarker for treatment monitoring.
TRIAL REGISTRATION: ClinicalTrials.gov , NCT03237754 . Registered 03 August 2017 - retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03237754 .

Keywords

Associated Data

ClinicalTrials.gov | NCT03237754

References

  1. Neuromodulation. 2021 Jul;24(5):890-898 [PMID: 33078518]
  2. Cephalalgia. 2007 Dec;27(12):1427-39 [PMID: 18034686]
  3. Neuroimage. 2014 Jul 1;94:287-302 [PMID: 24650594]
  4. J Headache Pain. 2013 Mar 11;14:23 [PMID: 23566101]
  5. Br J Psychiatry. 1999 May;174:449-54 [PMID: 10616615]
  6. Eur J Neurol. 2014 Feb;21(2):287-e13 [PMID: 24200371]
  7. Neuroimage. 2009 Nov 1;48(2):371-80 [PMID: 19559801]
  8. Cephalalgia. 2018 Jan;38(1):1-211 [PMID: 29368949]
  9. Neurol Clin. 2019 Nov;37(4):631-649 [PMID: 31563224]
  10. Curr Pain Headache Rep. 2012 Feb;16(1):93-100 [PMID: 22076672]
  11. Front Neurol. 2019 Dec 13;10:1325 [PMID: 31920945]
  12. Continuum (Minneap Minn). 2018 Aug;24(4, Headache):1032-1051 [PMID: 30074548]
  13. J Pain. 2013 Dec;14(12):1703-8 [PMID: 24290450]
  14. Cephalalgia. 2011 Feb;31(3):301-15 [PMID: 20813784]
  15. Cephalalgia. 2015 Aug;35(9):783-91 [PMID: 25414472]
  16. Headache. 2001 Jun;41(6):565-72 [PMID: 11437892]
  17. J Headache Pain. 2017 Dec;18(1):72 [PMID: 28730563]
  18. NMR Biomed. 2013 Jan;26(1):58-64 [PMID: 22674568]
  19. Neuroimage. 2000 Jun;11(6 Pt 1):805-21 [PMID: 10860804]
  20. Cephalalgia. 2015 Jan;35(1):3-9 [PMID: 24812034]
  21. Cephalalgia. 2003 May;23(4):264-70 [PMID: 12716343]
  22. Continuum (Minneap Minn). 2018 Aug;24(4, Headache):1052-1065 [PMID: 30074549]
  23. Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4687-92 [PMID: 11287655]
  24. J Headache Pain. 2020 Dec 7;21(1):141 [PMID: 33287704]
  25. Curr Opin Neurol. 2005 Jun;18(3):305-10 [PMID: 15891417]
  26. PLoS Med. 2006 Oct;3(10):e402 [PMID: 17048979]
  27. Headache. 2008 Jul;48(7):1044-55 [PMID: 18479421]
  28. J Headache Pain. 2020 Apr 25;21(1):39 [PMID: 32334532]
  29. Eur J Neurol. 2003 Jan;10(1):53-7 [PMID: 12534993]
  30. J Neurol Sci. 2017 Jul 15;378:225-232 [PMID: 28566169]
  31. Invest Ophthalmol Vis Sci. 2004 Feb;45(2):702-7 [PMID: 14744917]
  32. Radiology. 2013 Jul;268(1):170-80 [PMID: 23533286]
  33. Cephalalgia. 2011 Oct;31(14):1452-8 [PMID: 21911412]
  34. Handb Clin Neurol. 2015;131:447-63 [PMID: 26563803]
  35. J Physiol. 2000 Sep 15;527 Pt 3:633-9 [PMID: 10990547]
  36. J Clin Med. 2019 Dec 26;9(1): [PMID: 31888011]
  37. Brain Topogr. 2021 May;34(3):384-401 [PMID: 33606142]
  38. Pain. 2013 Dec;154 Suppl 1: [PMID: 24347803]
  39. Cephalalgia. 2019 Apr;39(5):665-673 [PMID: 30525946]
  40. J Headache Pain. 2020 Jul 11;21(1):89 [PMID: 32652927]
  41. Neurology. 2018 Jul 17;91(3):e280-e292 [PMID: 29925551]
  42. J Neurol Sci. 2015 Feb 15;349(1-2):33-9 [PMID: 25579414]
  43. Cephalalgia. 2016 Jan;36(1):67-91 [PMID: 25888584]
  44. J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):741-9 [PMID: 26733600]
  45. Curr Pain Headache Rep. 2016 Jul;20(7):44 [PMID: 27215627]
  46. Brain. 2020 Jun 1;143(6):e45 [PMID: 32363400]
  47. Neuroimage. 2007 Oct 15;38(1):95-113 [PMID: 17761438]
  48. Cephalalgia. 2011 May;31(7):820-8 [PMID: 21398419]
  49. Neurology. 2017 Nov 14;89(20):2066-2074 [PMID: 29021356]
  50. Cephalalgia. 2016 Feb;36(2):139-47 [PMID: 25926619]
  51. Headache. 2012 Jan;52(1):3-17 [PMID: 22106869]
  52. Front Hum Neurosci. 2014 Sep 02;8:669 [PMID: 25228870]
  53. J Psychiatry Neurosci. 2007 Jul;32(4):259-66 [PMID: 17653294]
  54. Brain. 2018 Mar 1;141(3):776-785 [PMID: 29360944]
  55. Mol Psychiatry. 2020 Feb;25(2):397-407 [PMID: 31455860]
  56. Pain Med. 2020 Nov 1;21(11):2997-3011 [PMID: 33040149]
  57. BMC Psychiatry. 2013 Nov 09;13:300 [PMID: 24206945]
  58. Neuroimage. 2005 Jul 1;26(3):839-51 [PMID: 15955494]
  59. Headache. 2012 Sep;52(8):1283-95 [PMID: 22512348]
  60. Brain. 2020 Dec 5;143(11):e93 [PMID: 33175960]
  61. Lancet Neurol. 2015 Jan;14(1):81-91 [PMID: 25496899]
  62. Cephalalgia. 2016 May;36(6):526-33 [PMID: 26378082]
  63. J Physiol. 1964 Aug;172:369-82 [PMID: 14199369]
  64. Curr Neurol Neurosci Rep. 2016 Jul;16(7):64 [PMID: 27181270]
  65. Lancet Neurol. 2018 Nov;17(11):954-976 [PMID: 30353868]
  66. Headache. 2008 Jan;48(1):109-17 [PMID: 18184293]
  67. Womens Midlife Health. 2020 Aug 05;6:7 [PMID: 32774872]
  68. Pain. 2011 Feb;152(2):254-258 [PMID: 21145169]
  69. Headache. 2019 Nov;59(10):1808-1820 [PMID: 31680242]
  70. Brain Res Bull. 2006 Feb 15;68(6):459-63 [PMID: 16459203]

MeSH Term

Cross-Sectional Studies
Gray Matter
Humans
Migraine Disorders
Single-Blind Method
Transcranial Direct Current Stimulation

Word Cloud

Created with Highcharts 10.0.0treatmenttDCSmigraineursgreymattervolumeoccipitalchangesmigraineStructuralalterationsstructuralepisodicMRIlingualgyrusdirectcurrentstimulationareascanstudyrandomizedbaseline15 months5controlsmorphometryleftTrackingplasticityBACKGROUND:OccipitaltranscranialeffectivesafeattackpreventionbrainfoundregionsrelatedpainmodulationperceptionincludingHoweverwhetherdynamicallymodulatedunderstudiedOBJECTIVE:tracklongitudinallyfivemonthssingle-blindsham-controlledMETHODS:24eitherreceiveverumsham28 daysinvestigatedynamicpatientsunderwentpriorcompletion31healthyscannedprotocolMorphometrymeasuresassessedratetimegroupsmeanstensor-basedRESULTS:reported6monthlydaysaveragecross-sectionalanalysisrevealedincreasescomparedFourweeksapplicationledreduction9days/monthparalleleddecreasesgroupextentoverlappingseenCONCLUSION:showsincreasedmodifiedprovidespotentialneuroimagingbiomarkermonitoringTRIALREGISTRATION:ClinicalTrialsgovNCT03237754Registered03August2017-retrospectivelyregisteredhttps://clinicaltrialsgov/ct2/show/NCT03237754inducedmigraine:controlledtrialBrainMigraineTranscranialVoxel-based

Similar Articles

Cited By